[Form 4] Wave Life Sciences Ltd. Insider Trading Activity

Rhea-AI Filing Summary

Gregory L. Verdine, a director of Wave Life Sciences Ltd. (WVE), received director compensation consisting of 12,700 restricted share units (RSUs) and a share option covering 76,200 ordinary shares with an exercise price of $8.105. Following the RSU grant, his reported direct beneficial ownership is 295,217 ordinary shares.

The RSUs vest 100% on the earlier of the company’s 2026 annual general meeting or August 11, 2026. The option vests on the same schedule and has an expiration date of August 11, 2030. Both awards were granted under the 2025 Non-Employee Director Compensation Policy.

Insights

Financial Analyst

TL;DR: Director Verdine received routine 2025 non-employee director awards: 12,700 RSUs and 76,200 options at $8.105 strike.

The Form 4 reports non-cash compensation typical for non-employee directors: a grant of 12,700 RSUs and a stock option for 76,200 shares with an $8.105 exercise price. Both awards vest by the earlier of the 2026 annual general meeting or August 11, 2026; the option expires August 11, 2030. The filing shows direct beneficial ownership of 295,217 shares after the RSU award. This disclosure is transactional and consistent with director compensation rather than an operational development.

Corporate Governance Expert

TL;DR: Grants conform to the company’s 2025 director compensation policy with clear vesting and expiration terms.

The filing documents standard equity-based compensation for a non-employee director under the 2025 Non-Employee Director Compensation Policy: a full-vesting RSU award and an option grant that vests on the same schedule. Vesting tied to the 2026 annual general meeting or August 11, 2026 is explicit, and the option’s August 11, 2030 expiration is stated. The disclosure is clear on amounts, form of ownership (direct), and exercise price ($8.105), meeting transparency expectations for Section 16 filings.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Verdine Gregory L.

(Last) (First) (Middle)

C/O WAVE LIFE SCIENCES LTD.,

733 CONCORD AVE.

(Street)

CAMBRIDGE MA 02138

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Wave Life Sciences Ltd. [ WVE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	08/11/2025		A		12,700(1)	A	$0.00	295,217	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (right to buy)	$8.105	08/11/2025		A		76,200		(2)	08/11/2030	Ordinary Shares	76,200	$0.00	76,200	D

Explanation of Responses:

1. The reporting person was granted this restricted share unit award (RSU) pursuant to the 2025 Non-Employee Director Compensation Policy. The RSU vests as to 100% of the shares on the earlier of the Company's 2026 annual general meeting or August 11, 2026.

2. The reporting person was granted this option pursuant to the 2025 Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2026 annual general meeting or August 11, 2026.

	/s/ Gregory L. Verdine	08/13/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity did Gregory L. Verdine acquire according to the WVE Form 4?

The Form 4 reports a grant of 12,700 RSUs and a share option for 76,200 ordinary shares.

What is the exercise price of the options granted to the WVE director?

The option has an exercise price of $8.105 per share.

When do the RSUs and options vest for the awards reported in the WVE Form 4?

Both the RSUs and the option vest 100% on the earlier of the company’s 2026 annual general meeting or August 11, 2026.

How many shares does Gregory Verdine beneficially own after the reported transaction?

The Form 4 reports 295,217 ordinary shares beneficially owned following the reported RSU grant.

When does the option granted in the WVE Form 4 expire?

The option expiration date stated in the filing is August 11, 2030.